Management of hemolytic uremic syndrome
David Kavanagh¹, Shreya Raman² and Neil S. Sheerin³*

Addresses: ¹Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK; ²Department of Histopathology, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK; ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

* Corresponding author: Neil S. Sheerin (neil.sheerin@ncl.ac.uk)

F1000Prime Reports 2014, 6:119 (doi:10.12703/P6-119)

All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/6/119

Abstract
Hemolytic uremic syndrome (HUS) is a disease characterized by hemolysis, thrombocytopenia, and acute kidney injury, although other organs may be involved. Most cases are due to infection with Shiga toxin-producing Escherichia coli (STEC). Early identification and initiation of best supportive care, with microbiological input to identify the pathogen, result in a favorable outcome in most patients. The remaining 10% of HUS cases are classed together as atypical HUS and have a diverse etiology. The majority are due to inherited or acquired abnormalities that lead to a failure to control complement activation. Atypical HUS occurring in other situations (for example, related to pregnancy or kidney transplantation) may also involve excessive complement activation. Plasma therapies can reverse defective complement control, and it is now possible to specifically target complement activation. This has led to improved outcomes in patients with atypical forms of HUS. We will review our current understanding of the pathogenesis of HUS and how this has led to advances in patient care.

Introduction
The thrombotic microangiopathies (TMAs) are a group of diseases that are characterized by a microangiopathic hemolytic anemia, thrombocytopenia, and the occlusion of small vessels by thrombi (Figure 1). Endothelial injury and an inability to control coagulation are common features of all of these diseases. The clinical manifestations of a TMA depend on the site of vascular involvement and, on the basis of clinical presentation, were classically divided into two main types: HUS and thrombotic thrombocytopenic purpura (TTP). HUS typically affects the microvasculature of the kidney causing acute kidney injury (AKI), whereas in TTP neurological disease is more common. However, it is clear that disease classification based purely on clinical presentation can be misleading, as HUS can cause neurological disease (as well as affecting many other organs) and TTP can affect the kidney. In addition, it is clear that HUS does not represent a single disease with a common pathogenesis. Instead, HUS is a group of diseases that are due to different environmental or genetic factors and that have a similar clinical presentation. As our understanding of the molecular basis of these diseases increases, it is now possible to classify HUS and TTP on the basis of etiology. Most cases of HUS follow infection with Shiga toxin-producing enteric pathogens or excessive activation of the complement system. TTP is due to diminished activity of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), an enzyme responsible for the breakdown of multimeric von Willebrand factor, a prothrombotic protein produced by the endothelium, megakaryocytes, and vascular connective tissue [1]. It is evident that a disruption of endothelium function is common to all TMAs and therefore it is possible that there are links between the pathways that lead to specific diseases.

Differentiating between types of TMA on the basis of clinical parameters is a vital part of patient care. However, this is not always possible, and diagnostic accuracy requires identification of the underlying abnormality. Accurate and early diagnosis is increasingly
important as new treatments become available that are specific for different types of TMA and with increasing evidence that early initiation of treatment improves patient outcomes. This review will discuss the pathogenic mechanisms that cause the different types of HUS, clinical and laboratory diagnosis of HUS, and the available treatment options.

**Pathogenesis of hemolytic uremic syndrome**

Although HUS is primarily a disease of the kidney, neurological involvement is common, potentially life-threatening, and an important determinant of mortality [2]. The incidence of HUS, usually as a consequence of infection, is higher in children; The overall incidence in the general population, including adults, is approximately 1 to 2 in 100,000 [3,4]. It can cause dialysis-requiring AKI, severe multi-organ failure, and death (<5%); however, in most cases, complete recovery occurs (75%), and the remaining patients have a reduced glomerular filtration rate, hypertension, or proteinuria [5]. Neurological involvement can present with irritability, confusion, focal deficit, seizures, or coma, and involvement of the heart, gastrointestinal tract, and pancreas has been described.

Most cases of HUS (90%) occur following infection with STEC, typically serotype O157. Other serotypes of *Escherichia coli* can produce toxin, and the largest recorded outbreak of STEC HUS occurred in Northern Europe in 2011 because of infection with serotype O104 [6]. Infection is acquired by ingestion of contaminated food and is followed about 3 days later, although not invariably [7], by abdominal pain and diarrhea that progresses to a colitic illness with bloody diarrhea (hence its previous name: diarrhea-positive HUS). Features of TMA and AKI develop over the following 3 to 4 days in 5% to 15% of patients with STEC infection [8]. Why only a small proportion of patients develop HUS following infection is not known. A genetic predisposition, perhaps involving genes associated with other forms of TMA, is possible, and complement gene mutations have been described in patients with STEC HUS and may predispose them to a poor outcome [9].

Pathogenic STEC strains express adhesins, which are thought to promote adherence to the intestinal epithelium following which there is translocation of toxin (usually Shiga toxin type 2) through the epithelium. It has been proposed that the toxin could then bind to circulating leukocytes [10–12], although the evidence for this is conflicting [13]. The Shiga toxin receptor is a glycosphingolipid: globotriaosylceramide (Gb3). When Shiga toxin binds Gb3, the complex is internalized and transported to the endoplasmic reticulum, where the complex is cleaved to release a protease into the cytoplasm. This protease inhibits ribosomal function and protein synthesis, leading to cell death. It can also activate signaling pathways, inducing an inflammatory response in affected cells [14]. Although Gb3 is found in other organs, the kidney is most susceptible to injury. This may be due to higher levels of Gb3 on renal cells, particularly the glomerular endothelium (but also podocytes, mesangial, and tubular epithelial cells [15]), the high blood flow to the kidney, or a greater susceptibility of renal cells to the effects of the toxin [16]. The expression of Gb3 at other sites (for example, within the central nervous system) explains the extra-renal manifestations of STEC HUS.
Atypical hemolytic uremic syndrome

Atypical HUS (aHUS) accounts for most of the remaining 10% of cases of HUS. With aHUS, as with STEC HUS, the kidneys are most frequently involved, but any organ can be affected. It is difficult to distinguish aHUS from STEC HUS or TTP on clinical grounds alone. A diagnosis of aHUS should be considered once STEC infection or reduced ADAMTS13 activity has been excluded. Although it is more common in childhood, aHUS can occur at any age and has a worse prognosis than STEC HUS, with a 3-year patient or kidney survival of 50% [17].

Genetic or acquired defects in control of complement activation are commonly found in patients with aHUS. Complement is a complex system of enzymes, effector proteins, and inhibitors and forms part of the innate immune system. Low levels of circulating complement protein C3, suggestive of consumption, were first described in 1973 [18]. Twenty-five years later, loss-of-function mutations in the complement regulatory protein complement factor H (CFH) were described [19]. Since that first report, loss-of-function mutations in other complement regulators (complement factor I [20] and membrane cofactor protein (CD46) [21]) or gain-of-function mutations in complement activators (C3 [22] and complement factor B [23]), gene rearrangement in CFH and its related proteins [24], autoantibodies affecting regulator function [25–27], and “at risk” haplotypes [28,29] have been described in patients with aHUS. An abnormality in complement control can be identified in approximately 65% of patients with HUS and is also described in other glomerular [30–32] and non-renal [33] diseases. aHUS is usually inherited as an autosomal dominant trait, and there is incomplete penetrance with approximately 50% of people with a mutation developing disease [34]. The incomplete penetrance may be explained by the need for an environmental trigger, which can include pregnancy [35], infection (including a diarrheal illness which can occur in 23% of patients [36]), or drugs [37]. The presence of more than one mutation or susceptible haplotype may also increase the risk of disease [36]. Complement activation, primarily via the alternative pathway, leads to endothelial damage and activation, leading to small-vessel thrombosis in target organs (Figure 2).

Not all cases of aHUS are due to defects in proteins traditionally regarded as important in complement control. Genetic variants in thrombomodulin, a protein with anti-fibrinolytic and anti-inflammatory properties, have been associated with aHUS [38,39]. Thrombomodulin also accelerates the factor I-mediated cleavage of C3b, and loss of this effect may predispose to aHUS [38]. However, these variants can occur in the general population and may vary in combination with other disease-associated mutations [39,40]. In early childhood, recessive mutations in diacylglycerol kinase epsilon (DGKE) cause an HUS-like TMA that frequently progresses to renal failure [41,42]. How DGKE mutations cause TMA is not known, but defective DGKE signaling appears to promote a pro-thrombotic state.

Other forms of hemolytic uremic syndrome

Thrombotic microangiopathic diseases with clinical, hematological, and histological features of HUS can occur in response to other triggers. Infection with neuraminidase-producing Streptococcus pneumoniae account for 5% of childhood HUS, inducing a severe TMA with high mortality [43]. One hypothesis for the link between infection and HUS is that neuraminidase strips N-acetylgalactosamine from the glyocalyx of cells exposing epitopes on endothelial cells, erythrocytes, and platelets that are recognized by naturally occurring antibodies, leading to a pro-thrombotic state. Treatment is supportive with eradication of Streptococcal infection.

An autosomal recessive defect in vitamin B12 metabolism leads in early childhood to severe TMA, which can be controlled with daily vitamin B12 treatment [44,45]. The use of quinine is associated with a TMA [46,47] as are other drugs, in particular calcineurin inhibitors [48,49]. Infections (for example, HIV [50] and malignancy or its treatment [51]) are also associated with TMA and renal involvement. In some of these cases, particularly those related to pregnancy, the association may reflect a triggering event in patients carrying a genetic defect in complement control. In a series of patients with pregnancy-induced HUS, over 80% had a complement gene mutation [35].

Diagnosis and treatment of patients with STEC hemolytic uremic syndrome

A diagnosis of STEC HUS should be considered in any patient developing a TMA, particularly if it follows a diarrheal illness and is associated with AKI. However, atypical forms of HUS also may be associated with diarrhea and therefore STEC infection should be confirmed (Figure 3). Stool samples should be sent for STEC culture, but this may be negative, particularly if sample collection is delayed [52]. Diarrhea may have stopped by the time of presentation, but STEC can still be cultured from feces or rectal swab. Samples should also be assessed for the presence of Shiga toxin [53]. Shiga toxin can be detected directly from feces, but the results are variable [54], and this is best performed after overnight culture. Polymerase chain reaction-based assays can be used to detect STEC Shiga toxin genes [55]. Serology can also be useful indicator of STEC infection [56].
Best supportive care (BSC), with particular attention to fluid replacement, renal support, and treatment of neurological manifestations of the disease, is the mainstay of treatment for patients with HUS [57,58]. The improved survival in patients with STEC HUS in recent years probably reflects better supportive care. Evidence for the addition of plasma-based therapy to BSC for the treatment for STEC HUS is limited and it probably has no role [59,60]. There was a report from the 1990s suggesting a reduced mortality in older patients treated

Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; HUS, hemolytic uremic syndrome; LDH, lactate dehydrogenase; PCR, polymerase chain reaction; STEC, Shiga toxin-producing Escherichia coli; TTP, thrombotic thrombocytopenic purpura.
with plasma exchange [61]. However, several studies have found no benefit or worse outcomes following treatment with plasma therapies [59,60], including a prospective study of 619 children [62] and analysis of outcomes from the German outbreak [63,64].

The use of antibiotics is controversial. It is recommended not to use antibiotics to treat STEC infection (*E. coli* O157) because of either no benefit or potential increase in the risk of developing HUS [63–68]. There is evidence that antibiotic use leads to an increase in toxin production [69] or release [70]. A study from Japan reported a lower rate of HUS in patients with STEC infection treated with fosfomycin [71]. However, this was evident only on subgroup analysis of the fosfomycin-treated cohort, and patients in the control cohort may have received other antibiotics. A beneficial effect of fosfomycin is therefore unproven. A subsequent meta-analysis failed to show a harmful or beneficial effect of antibiotics but included the subgroup analysis from the Japanese study [72,73]. Data from the 2011 German outbreak with *E. coli* O104 support the use of antibiotics in patients with established STEC HUS, with a reduction in seizures, deaths, and requirement for abdominal surgery when combined antibiotics were used [63]. Antibiotics also eliminate STEC from the gut more rapidly [74] but will have no effect on the individual patient. It may be that the results from the German outbreak due to *E. coli* O104 may not be generalizable to infections with other serotypes as *E. coli* O104, in contrast to O157, does not release increased quantities of Shiga toxin in response to therapeutic concentrations of antibiotics [75].

There is evidence from a pre-clinical rodent model of Shiga toxin-mediated injury that complement activation may augment the effects of the toxin on cells [76,77], although no evidence of complement activation was seen in a primate model [78]. There is also evidence of complement activation in the circulation of patients with STEC HUS [79], and a report of three children with severe neurological involvement suggested a response to treatment with the anti-C5 monoclonal antibody, eculizumab [80]. Eculizumab was used extensively during the German outbreak with no reported benefit.
in adolescents and adults with plasma therapy-resistant or -dependent aHUS have recently been reported. In total, 37 patients were treated in these open-label, uncontrolled trials. Eculizumab was effective in more than 80% of patients, controlling hemolysis, improving renal function, and allowing the withdrawal of plasma therapy [95]. Treatment of aHUS should be started early (as soon as other causes of TMA have been excluded on the basis of clinical and laboratory assessment) since early treatment is associated with a better renal outcome [96]. There are still unanswered questions about eculizumab treatment of aHUS, in particular how long to continue treatment. Withdrawal of eculizumab is associated with relapse, but it can be withdrawn in some patients, with a recent report describing successful withdrawal in 7 out of 10 patients [97]. Because of the risk of Neisseria meningitides infection, all patients receiving eculizumab should be vaccinated and long-term antibiotics should be considered [98].

The rationale for anti-complement treatment in patients without a defined defect in complement control or with a non-complement mutation is less clear. Nevertheless, patients without an identified mutation responded similarly to treatment with eculizumab [95], which may reflect a role for complement in the development of aHUS, even if the causative mutation lies outside the complement system. There are also links between thrombomodulin and complement activation. The exception is patients with DGKE mutations who appear resistant to treatment targeting complement activation [41].

Transplantation in patients with hemolytic uremic syndrome
Although STEC frequently causes AKI, recovery of renal function usually occurs. Recovery of function may not be complete, and in some cases maintenance dialysis is required. In these cases, transplantation is possible provided that there is no coexisting defect in complement control [9]. In contrast, aHUS frequently recurs after transplantation. Overall, 60% of patients develop recurrent disease after transplantation, 90% of whom will lose their graft [99]. The risk of recurrence depends on the underlying abnormality, with high risk in patients with factor H, C3, and B mutations but lower risk with CD46 mutations or if no abnormality is detected [99–101]. Recurrent disease after transplantation can be treated successfully with eculizumab, and 40% of patients in the recent trials developed disease in a transplanted kidney [95,102]. Eculizumab can also be used prophylactically to prevent recurrence in patients at high risk of recurrence who are undergoing transplantation [96].

As most complement proteins are synthesized in the liver (with the exception of CD46), combined liver and kidney
transplantation reverses the complement abnormality, controls disease, and allows successful kidney transplantation [103,104]. Initial outcomes of combined transplantation were poor [105]. Aggressive plasma exchange or ecilizumab to correct the complement abnormality prior to transplantation allows successful transplantation and this option should be discussed with patients [106].

If the predisposing mutation occurs in other pathways, aHUS can recur after transplantation. Recurrence after transplantation has been reported in patients with thrombomodulin mutations [38,107]. Transplantation has been performed in patients with aHUS due to DGKE mutations without evidence of recurrent aHUS [41].

The etiology of de novo HUS after transplantation is complex, and ischemia reperfusion, drugs, and humoral immunity are potential precipitants. Complement may also be involved. Thirty percent of patients who develop de novo HUS have a complement mutation [108], and even in the absence of a mutation ecilizumab can be effective [109].

**Conclusions**

Most commonly, HUS is due to STEC infection. This can be a severe, life-threatening disease but in most cases is self-limiting and will resolve completely. Treatment is with BSC, and although other treatments, including plasma therapy, ecilizumab, and toxin binders, have been proposed, there is very little evidence to support their use outside of clinical trials. aHUS is, in most cases, due to impaired control of complement activation. It can be treated effectively with complement inhibition, but this may not be successful if treatment is started late or the disease is caused by a problem in another pathway.

Undoubtedly, progress has been made in the treatment of HUS. However, there are very few high-quality clinical trials to guide treatment. HUS is a rare, etiologically heterogeneous disease and there is a need for multi-center collaborative studies to test the efficacy of new treatments and inform best practice in the treatment of this disease.

**Abbreviations**

ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS, atypical hemolytic uremic syndrome; AKI, acute kidney injury; BSC, best supportive care; CFH, complement factor H; DGKE, diacylglycerol kinase epsilon; Gb3, globotriaosylceramide; HUS, hemolytic uremic syndrome; PE, plasma exchange; STEC, Shiga toxin-producing *Escherichia coli*; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.

**Disclosures**

David Kavanagh and Neil Sheerin have received support to attend meetings and honoraria for presentations from Alexion Pharmaceuticals (Cheshire, CT, USA). Shreya Raman declares that she has no disclosures.

**References**

1. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B: Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997, 89:3097-103.
2. Bale JF, Jr., Brasher C, Siegler RL: CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis. Am J Dis Child 1980, 134:869-72.
3. Trachtman H, Austin C, Lewinski M, Stahl RA: Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012, 8:658-69.
4. Lynn RM, O'Brien SJ, Taylor CM, Adak GK, Chart H, Cheasty T, Cola JE, Gillespie IA, Locking ME, Reilly WJ, Smith HR, Waters A, Willshaw GA: Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005, 11:590-6.
5. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF: Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. Jama 2003, 290:1360-70.
6. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner B, Buchholz U, Stark K, Krause G: HUS Investigation Team: Epidemiic profile of Shiga-toxin-producing *Escherichia coli* O104:H4 outbreak in Germany. N Engl J Med 2011, 365:1771-80.
7. Miceli S, Jure MA, de Saab OA, de Castillo MC, Rojas S, de Holgado AP, de Nader OM: A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina. Jpn J Dis Inf 1999, 52:33-7.
8. Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing *Escherichia coli* and haemolytic haemorrhagic syndrome. Lancet 2005, 365:1073-86.
9. Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M: Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 2013, 13:2201-6.
10. Brigotti M, Caprioli A, Tozzi AE, Tazzari PL, Ravanelli E, Ricci F, Conte R, Carnicelli D, Procaccino MA, Minelli F, Ferretti AV, Pagliaronga F, Edesfanti A, Rizzoni G: Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol 2006, 44:313-7.
11. Brigotti M, Tazzari PL, Ravanelli E, Carnicelli D, Rocchi L, Arfìlli V, Scavia G, Minelli F, Ricci F, Pagliaro P, Ferretti AV, Pecoraro C, Pagliaronga F, Edesfanti A, Procaccino MA, Tozzi AE, Caprioli A: Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Pediatr Infect Dis J 2011, 30:486-90.
12. Brigotti M, Carnicelli D, Ravanelli E, Barbieri S, Ricci F, Bontadini A, Tozzi AE, Scavia G, Caprioli A, Tazzari PL: Interactions between Shiga toxins and human polymorphonuclear leukocytes. J Leukoc Biol 2008, 84:1019-27.
13. Geelen JM, van der Velden TJ, Te Loo DM, Boerman OC, van den Heuvel LP, Monnens LA: Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leukocytes. Nephrol Dial Transplant 2007, 22:749-53.
14. Obrig TG: *Escherichia coli* Shiga Toxin Mechanisms of Action in Renal Disease. Toxins (Basel) 2010, 2:2769-94.
in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome. Microb Pathog 2001, 31:59-67.

16. Obrig TG, Louise CB, Lingwood CA, Boyd B, Harley-Malone Y, Daniel TO: Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993, 268:15644-8.

17. Noris M, Caprioli J, Bresin E, Miosi C, Panetti G, Gamba S, Daina E, Feilli C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-59.

18. Cameron JS, Vicks R: Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 1973, 2:297.

19. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998, 53:836-44.

20. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Frédman VH: Complement factor I: a susceptibility gene for atypical haemolytic uremic syndrome. J Med Genet 2004, 41:e84.

21. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorre R, Muslumangli MH, Kawukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003, 100:2966-71.

22. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Frédman VH, Janssen BJ, Goodship TH, Atkinson JP: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112: 4948-52.

23. Goicoechea de Jorge E, Harris CL, Eparza-Gordillo J, Carreras Llopis-Trascasa M, Sanchez-Corral P, Morgan BP, Rodrigues de Cordoba S: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007, 104:240-5.

24. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH: Complement factor I-related macular degeneration susceptibility: a meta-analysis. Genet Med 2014, 16:300-2.

25. Kavanagh D, Pappworth IY, Hayes CM, Moore I, Anderson H, Atkinson JP, Goodship JA, Richards A: Alternative pathway complement proteins in American Society of Nephrology. Clin J Am Soc Nephrol 2008, 3:1267-79.

26. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Frédman VH: Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 2014, 124:145-55.

27. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Machaer MA, Zuber J, Karras A, Provot F, Moulin B, Gruenfeld JP, Niaudet P, Lesavr P, Fremeaux-Bacchi V: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012, 82:454-64.

28. Wang X, Geng P, Zhang Y, Zhang M: Association between complement factor H Val62Ile polymorphism and age-related macular degeneration susceptibility: a meta-analysis. Gene 2014, 538:306-12.

29. Caprioli J, Noris M, Bresin E, Liszewski MK, Liszewski G, Castelletti F, Betzington P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni P, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G: International Registry of Recurrent and Familial HUS/TTP: Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-79.

30. Fremeaux-Bacchi V, Dragon-Durey MA, Frédman VH, Voskarides K, Deltas C, Palmer A, Fremeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC: Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010, 376:794-801.
Naude P, Deschénes G, Lebranchu Y, Zuber J, Liorat C: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:534-62.

41. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobil M, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Liorat C, Litton RP: Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45:531-6.

42. Ozaltin F, Li B, Rauhauser A, An SW, Soylermezoglu O, Gonul, II, Taskiran EZ, Isbirilguo T, Korkmaz E, Bilginer Y, Duzova A, Ozen S, Topaloglu R, Besbas N, Ashraf S, Du Y, Liang C, Chen P, Lu D, Vadvagara K, Arbuckle S, Lewis D, Wakeland BK, Quigg RJ, Ransom RF, Wakeland EK, Topham MK, Bazan NG, Mohan C, Hildebrandt F, Bakkaloglu A, Huang CL, Artanasio M: DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013, 24:377-84.

43. Copelovitch L, Kaplan BS: Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 2008, 23:1951-6.

44. Kind T, Levy J, Lee M, Kaicker S, Nicholson JF, Kane SA: Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period. J Pediatr Hematol Oncol 2002, 24:327-9.

45. Sharma AP, Greenberg CR, Prasad AN, Prasad C: Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol 2007, 22:2097-103.

46. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH: Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood 1991, 77:306-10.

47. Gottschall JL, Neuringer B, McFarland JG, Wu GG, Weitekamp LA, Aster RH: Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994, 47:283-9.

48. Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD: De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985, 98:54-62.

49. Medina PJ, Sipols JM, George JN: Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001, 8:286-93.

50. Turner ME, Kher K, Rakusan T, D’Angelo L, Kapur S, Selby D, Ray PE: A typical hemolytic uremic syndrome in human immunodeficiency virus-infected children. Pediatr Nephrol 1997, 11:161-3.

51. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazza L, Schein PS, et al.: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989, 7:781-9.

52. Mody RK, Luna-Gierke RE, Jones TF, Comstock N, Hurd S, Scheftel J, Lathrop S, Smith G, Palmer A, Strockbine N, Talkington D, Mahon BE, Hoekstra RM, Griffin PM: Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 2012, 166:902-9.

53. Klein EJ, Stapp JR, Clausen CR, Boster DR, Wells JG, Qin X, Swardlow DL, Tarr PI: Shiga toxin-producing Escherichia coli in children with diarrhoea: a prospective point-of-care study. J Pediatr 2002, 141:172-7.

54. Cornick NA, Jelacic S, Ciol MA, Tarr PI: Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. J Infect Dis 2002, 185:57-63.

55. Gerratzen A, Wittke JW, Wolff D: Rapid and sensitive detection of Shiga toxin-producing Escherichia coli directly from stool samples by real-time PCR in comparison to culture, enzyme immunoassay and Vero cell cytotoxicity assay. Clin Lab 2011, 57:993-8.

56. Chart H, Chestey T: Human infections with verocytotoxin-producing Escherichia coli O157-10 years of E. coli O157 serodiagnosis. J Med Microbiol 2008, 57:1389-93.

57. Michael M, Elliot EJ, Craig JC, Ridley G, Hodson EM: Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 53:259-72.

58. Michael M, Elliot EJ, Ridley GF, Hodson EM, Craig JC: Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009:CD003595.

59. Rizzoni G, Claris-Appiani A, Edefonti A, Facchin P, Franchini F, Gusnano R, Imbasciati E, Papavero L, Perfumo F, Remuzzi G: Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1998, 112:284-90.

60. Loos S, Ahlenstiel T, Kranz B, Staudé H, Pape L, Hartel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Muller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, Konig J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ: An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012, 55:753-9.

61. Dudas S, Murphy J, Soural RT, Jones GA, Hutchinson SJ, Todd WT: Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999, 354:1327-30.

62. Rosales A, Hofer J, Zimmerhackl LB, Jungfraitmayr TC, Riedl M, Giner T, Strasak A, Orth-Holler D, Wurzner R, Karch H, German-American HUS/SG: Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012, 54:1413-21.

63. Menne J, Nitschke M, Stingle R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunckhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gergk C, Goetschke A, Greme J, Hafer C, Hagenmüller F, Hafner H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehlbacher M, Kunzendorf U, Lehnert H, Manns MP: Validation of treatment strategies for enterohaemorrhagic Escherichia
71. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K: Urinary tract infection. J Urol 2000, 164:461.
72. Safdar N, Said A, Gangnon RE, Maki DG: Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. Pediatr Infect Dis J 2012, 31:37-41.
73. Wong CS, Jelacic S, Habeeb RL, Watkins SL: Risk factors for the hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. Pediatrics 1997, 100:12.
74. Kimmitt PT, Harwood CR, Barer MR: Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 2000, 6:548-55.
75. Grif K, Dierich MP, Karch H, Allerberger F: Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998, 17:761-6.
76. Ikeda O, Kino K, Takatora T, Nakahashi N, Tataraka K: Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999, 52:357-62.
77. Safdar N, Said A, Gangnon RE, Maki DG: Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002, 288:996-1001.
78. Wong CS, Brandt JR: Risk of hemolytic uremic syndrome from antibiotic treatment of Escherichia coli O157:H7 colitis. JAMA 2002, 288:3111; author reply 3112.
79. Nitschke M, Sayk F, Hartl C, Rosendal RT, Hauswaldt L, Steinhoff J, Fellermann K, Derad I, Wellhoner P, Boppel T, Karch H: Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enterohaemorrhagic Escherichia coli O157:H4. JAMA 2012, 307:1046-52.
92. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P: Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:621-4.

93. Prescott HC, Wu HM, Cataland SR, Baiocchi RA: Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 2010, 85:976-7.

94. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD: Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 2011, 26:2085-8.

95. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranche Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-81.

96. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V: Use of eculizumab for atypical haemolytic uremic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-57.

97. Ardissino G, Testa S, Possenti I, Tel F, Pagialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M: Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases. Am J Kidney Dis 2014, 64:633-7.

98. Wong EK, Goodship TH, Goodship TH: Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013, 56:199-212.

99. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G: Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1:88-99.

100. Noris M, Remuzzi G: Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010, 10:1517-23.

101. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonksi M, Lionet A, Chatellet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Frémeaux-Bacchi V: Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-75.

102. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, La Roché A, Heyne N, Ardissino G, Chatellet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS: Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:2337-54.

103. Saland JM, Ruggenenti P, Remuzzi G: Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20:940-9.

104. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH: Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006, 6:1948-52.

105. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M: Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005, 5:144-50.

106. Saland J: Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol 2014, 29:329-32.

107. Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L: Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant 2013, 17:E177-81.

108. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Frémeaux-Bacchi V: Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008, 8:1694-701.

109. Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM: Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011, 92:e42-3.